Medical laser platform to induce and monitor drug release from nano-constructs in vitro and in vivo

Zoe Ylöniemi; Johannes Kivelä; Elias Kokko; Robert Perttilä; Visa Kaivosoja; Lasse Orsila; Petteri Uusimaa

doi:10.1117/12.2577225

5 March 2021 Medical laser platform to induce and monitor drug release from nano-constructs in vitro and in vivo

Zoe Ylöniemi, Johannes Kivelä, Elias Kokko, Robert Perttilä, Visa Kaivosoja, Lasse Orsila, Petteri Uusimaa

Proceedings Volume 11624, Visualizing and Quantifying Drug Distribution in Tissue V; 116240K (2021) https://doi.org/10.1117/12.2577225
Event: SPIE BiOS, 2021, Online Only

Abstract

Fighting cancer involves more and more combination of modalities and drugs to maximize the long-term tumor resistance and cure. The rationale for combination therapy is to use treatment modalities or drug combinations that work by different mechanisms, decreasing the likelihood that resistant cancer cells will develop. The combination of light induced therapy like photodynamic therapy (PDT) and chemotherapy has the potential to overcome the limitations traditionally associated with light-based therapies and simultaneously limit the well-known adverse effects of chemotherapy by controlling local release and dose. Modulight ML7710i medical laser systems have not only been shown to unleash the cytotoxic potential of different photochemotherapeutic compounds but also to effectively monitor the drug release process providing clinicians real-time information on treatment progress and preliminary projections on treatment outcome. In vitro and in vivo experiments suggest that Modulight ML7710i lasers are capable of inducing drug release from liposomes with different mechanisms depending on the nano-construct and laser wavelength. Near infrared wavelengths such as 808 nm are capable of disturbing liposomal bilayer upon light energy conversion to heat by dyes like indocyanine green.¹Red wavelengths such as 665 nm in turn can induce photodynamic effect also causing drug release from hydrophobic core of the liposome.² Modulight ML7710i medical lasers are being validated for both use-cases and also for use with other dyes. The only limitation in using treatment monitoring capability is that the chemotherapeutic must have fluorescent potential. Modulight medical lasers can host multiple wavelengths within one system so that the drug release and the excitation can happen with different wavelengths if required.

Conference Presentation

Citation Download Citation

Zoe Ylöniemi, Johannes Kivelä, Elias Kokko, Robert Perttilä, Visa Kaivosoja, Lasse Orsila, and Petteri Uusimaa "Medical laser platform to induce and monitor drug release from nano-constructs in vitro and in vivo", Proc. SPIE 11624, Visualizing and Quantifying Drug Distribution in Tissue V, 116240K (5 March 2021); https://doi.org/10.1117/12.2577225

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available